---
layout: post
title: "FDA and drug development pipeline"
author: Shicheng Guo
date: 1918-02-28
categories: bioinformatics
tags: Genetics Genomics FDA Drug
---

* TAGRISSO: Targeted therapies to cancer that has tested positive for certain types of EGFR mutations. TAGRISSO specifically targets and blocks mutated EGFR found on cancer cells.
* [Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD)](https://en.wikipedia.org/wiki/Fragment-based_lead_discovery)
* BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene 
* The Drug Development Process: [The Drug Development Process](https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process)
* In order to incentivize the development of new drugs, the FDA grants drug developers market exclusivity for a period of five years after a new drug is approved, during which time, no other firm is permitted to sell the drug, whether or not it is protected by a patent.
* China National PGx Data Science Consortium (CNPGx)
* KEGG DRUG: Methotrexate	https://www.genome.jp/dbget-bin/www_bget?dr:D00142
